应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02315 百奥赛图-B
耶稣受难节休市 03-28 16:08:03
8.650
-0.210
-2.37%
最高
9.130
最低
8.650
成交量
13.65万
今开
9.000
昨收
8.860
日振幅
5.42%
总市值
34.55亿
流通市值
9.58亿
总股本
3.99亿
成交额
120.82万
换手率
0.12%
流通股本
1.11亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
一图看懂百奥赛图-B(02315.HK)2023年度业绩
格隆汇资讯 · 03-27 18:20
一图看懂百奥赛图-B(02315.HK)2023年度业绩
盈利拐点将至,百奥赛图-B(02315)“千鼠万抗”成长潜力加速释放
智通财经 · 03-27 18:19
盈利拐点将至,百奥赛图-B(02315)“千鼠万抗”成长潜力加速释放
百奥赛图-B(02315)发布2023年度业绩 收益7.17亿元 同比增加34.3%
智通财经 · 03-27 18:16
百奥赛图-B(02315)发布2023年度业绩 收益7.17亿元 同比增加34.3%
《公司业绩》百奥赛图-B(02315.HK)全年亏损收窄至3.83亿元人民币
阿斯达克财经 · 03-27 18:08
《公司业绩》百奥赛图-B(02315.HK)全年亏损收窄至3.83亿元人民币
百奥赛图-B盘中异动 大幅拉升5.08%
自选股智能写手 · 03-27 11:03
百奥赛图-B盘中异动 大幅拉升5.08%
百奥赛图与ABL Bio达成合作,共同开发新型双抗ADC药物
美通社 · 03-25
百奥赛图与ABL Bio达成合作,共同开发新型双抗ADC药物
百奥赛图-B(02315)下跌5.11%,报8.54元/股
金融界 · 03-22
百奥赛图-B(02315)下跌5.11%,报8.54元/股
百奥赛图-B盘中异动 股价大跌5.12%
自选股智能写手 · 03-22
百奥赛图-B盘中异动 股价大跌5.12%
百奥赛图-B(02315.HK)拟3月27日举行董事会会议考虑及批准全年业绩
格隆汇资讯 · 03-15
百奥赛图-B(02315.HK)拟3月27日举行董事会会议考虑及批准全年业绩
百奥赛图-B盘中异动 大幅拉升5.10%
自选股智能写手 · 03-14
百奥赛图-B盘中异动 大幅拉升5.10%
百奥赛图-B(02315)上涨5.4%,报10.54元/股
金融界 · 03-13
百奥赛图-B(02315)上涨5.4%,报10.54元/股
百奥赛图-B盘中异动 股价大涨5.39%
自选股智能写手 · 03-13
百奥赛图-B盘中异动 股价大涨5.39%
百奥赛图-B(02315)上涨7.18%,报10.0元/股
金融界 · 03-12
百奥赛图-B(02315)上涨7.18%,报10.0元/股
百奥赛图-B盘中异动 下午盘大幅拉升5.04%报9.801港元
自选股智能写手 · 03-12
百奥赛图-B盘中异动 下午盘大幅拉升5.04%报9.801港元
百奥赛图-B盘中异动 大幅跳水6.02%报8.901港元
自选股智能写手 · 03-11
百奥赛图-B盘中异动 大幅跳水6.02%报8.901港元
百奥赛图-B(02315)上涨6.43%,报9.1元/股
金融界 · 03-08
百奥赛图-B(02315)上涨6.43%,报9.1元/股
百奥赛图-B盘中异动 股价大涨5.26%
自选股智能写手 · 03-08
百奥赛图-B盘中异动 股价大涨5.26%
百奥赛图-B(02315)下跌5.0%,报8.55元/股
金融界 · 03-07
百奥赛图-B(02315)下跌5.0%,报8.55元/股
百奥赛图-B盘中异动 下午盘股价大跌5.00%报8.551港元
自选股智能写手 · 03-07
百奥赛图-B盘中异动 下午盘股价大跌5.00%报8.551港元
百奥赛图-B盘中异动 快速上涨5.08%
自选股智能写手 · 03-06
百奥赛图-B盘中异动 快速上涨5.08%
公司概况
公司名称:
百奥赛图-B
所属市场:
SEHK
上市日期:
--
主营业务:
北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。该公司运营两个业务部门。药物开发业务部门主要从事肿瘤学和自身免疫性疾病治疗的研发,及抗体开发业务。临床前研究服务部门主要从事基因编辑、临床前药理药效评估及模式动物销售。
发行价格:
--
{"stockData":{"symbol":"02315","market":"HK","secType":"STK","nameCN":"百奥赛图-B","latestPrice":8.65,"timestamp":1711613283016,"preClose":8.86,"halted":0,"volume":136500,"delay":0,"floatShares":110781920,"shares":399398420,"eps":-1.7024643,"marketStatus":"耶稣受难节休市","marketStatusCode":7,"change":-0.21,"latestTime":"03-28 16:08:03","open":9,"high":9.13,"low":8.65,"amount":1208240,"amplitude":0.054176,"askPrice":8.85,"askSize":5000,"bidPrice":8.64,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-1.4250609973001522,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1712021400000},"adr":0,"listingDate":1661961600000,"adjPreClose":8.86,"openAndCloseTimeList":[[1711589400000,1711598400000],[1711602000000,1711612800000]],"volumeRatio":0.991285403698008,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02315/wiki","defaultTab":"wiki","newsList":[{"id":"2422698129","title":"一图看懂百奥赛图-B(02315.HK)2023年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2422698129","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2422698129?lang=zh_cn&edition=full","pubTime":"2024-03-27 18:20","pubTimestamp":1711534808,"startTime":"0","endTime":"0","summary":"3月26日晚间,百奥赛图-B(02315.HK)发布截至2023年12月31日止年度业绩,2023年度,集团实现营收达人民币7.17亿元(单位下同),同比增长34%,其中海外营收达4.08亿元,同比增长66%,毛利率71%,基本稳定在较高水平。下面将通过一图看懂百奥赛图-B(02315.HK)2023年度业绩。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271820528b69548b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271820528b69548b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422473966","title":"盈利拐点将至,百奥赛图-B(02315)“千鼠万抗”成长潜力加速释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2422473966","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422473966?lang=zh_cn&edition=full","pubTime":"2024-03-27 18:19","pubTimestamp":1711534776,"startTime":"0","endTime":"0","summary":"“节流”方面,“千鼠万抗”抗体序列库搭建完成,标志着大规模研发已然告一段落。未来,百奥赛图亦将更加聚焦于模式动物及临床前CRO服务、抗体开发转让两方面的业务重心,加强自身业务专注度。截至目前,RenMab小鼠关键技术已获得中美两国的专利授权,彰显了公司领先的技术实力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032718241087bbf195&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032718241087bbf195&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422679966","title":"百奥赛图-B(02315)发布2023年度业绩 收益7.17亿元 同比增加34.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422679966","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422679966?lang=zh_cn&edition=full","pubTime":"2024-03-27 18:16","pubTimestamp":1711534600,"startTime":"0","endTime":"0","summary":"公告称,毛利由截至2022年12月31日止年度的约3.92亿元增加29.2%至截至2023年12月31日止年度的约5.06亿元,毛利增加主要是由于模式动物销售及抗体开发的收益增加。基于高度多样化的抗体库,集团拟主动探索与领先生物制药公司建立战略协同合作伙伴关系。该抗体库品质高且多样性丰富,能全面充分覆盖靶点的所有抗原表位,形成全人源抗体库,以满足各合作伙伴制药公司的不同抗体开发需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1093480.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422966393","title":"《公司业绩》百奥赛图-B(02315.HK)全年亏损收窄至3.83亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2422966393","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422966393?lang=zh_cn&edition=full","pubTime":"2024-03-27 18:08","pubTimestamp":1711534080,"startTime":"0","endTime":"0","summary":"百奥赛图-B(02315.HK) 公布截至去年12月底止全年业绩,营业额7.17亿元人民币(下同),按年升34.3%。亏损收窄至3.83亿元,上年同期蚀6.02亿元;每股亏损0.96元。不派息。(su/a)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2023/08/28中期业绩无派息2023/03/27末期业绩无派息 AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20221007162300628_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20221007162300628_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1337767/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422985025","title":"百奥赛图-B盘中异动 大幅拉升5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422985025","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422985025?lang=zh_cn&edition=full","pubTime":"2024-03-27 11:03","pubTimestamp":1711508597,"startTime":"0","endTime":"0","summary":"2024年03月27日早盘11时03分,百奥赛图-B股票出现波动,股价急速拉升5.08%。截至发稿,该股报9.290港元/股,成交量4.25万股,换手率0.04%,振幅6.67%。机构评级方面,在所有1家参与评级的机构中,100%的券商给予卖出建议,无券商给予买入、持有建议。百奥赛图-B股票所在的生物技术行业中,整体跌幅为0.59%。百奥赛图-B公司简介:北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271103177a4f5b9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271103177a4f5b9f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422559318","title":"百奥赛图与ABL Bio达成合作,共同开发新型双抗ADC药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2422559318","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2422559318?lang=zh_cn&edition=full","pubTime":"2024-03-25 16:54","pubTimestamp":1711356840,"startTime":"0","endTime":"0","summary":"北京2024年3月25日 /美通社/ -- 百奥赛图(北京)医药科技股份有限公司,一家创新技术驱动抗体类新药研发的国际性生物技术公司今日宣布与ABL Bio Inc.,一家处于临床阶段开发新型肿瘤和中枢神经系统疾病疗法的韩国生物技术公司达成合作,共同开发新型双特异性抗体偶联药物。百奥赛图RenLite小鼠平台可产生识别不同表位且亲和力高的全人抗体。百奥赛图董事长兼CEO沈月雷博士表示:\"我们很高兴和ABL达成合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4369592_ZH69592_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2421885923","title":"百奥赛图-B(02315)下跌5.11%,报8.54元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2421885923","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2421885923?lang=zh_cn&edition=full","pubTime":"2024-03-22 14:42","pubTimestamp":1711089725,"startTime":"0","endTime":"0","summary":"3月22日,百奥赛图-B(02315)盘中下跌5.11%,截至14:42,报8.54元/股,成交109.96万元。百奥赛图(北京)医药科技股份有限公司是一家以创新技术驱动新药研发为主营业务的生物技术公司,拥有自主研发并拥有完全独立知识产权的全人抗体RenMiceTM平台,已建立起12项核心药物产品管线。公司正在对1000多个潜在可成药的靶点进行规模化药物开发,已签署了24项药物合作开发协议并与14家企业达成RenMice平台授权合作。截至2023年中报,百奥赛图-B营业总收入3.27亿元、净利润-1.9亿元。3月27日,百奥赛图-B将披露2023财年年报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/22144239954359.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2421859642","title":"百奥赛图-B盘中异动 股价大跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2421859642","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421859642?lang=zh_cn&edition=full","pubTime":"2024-03-22 14:41","pubTimestamp":1711089719,"startTime":"0","endTime":"0","summary":"2024年03月22日下午盘14时41分,百奥赛图-B股票出现异动,股价大幅下挫5.12%。截至发稿,该股报8.540港元/股,成交量12.6万股,换手率0.11%,振幅6.11%。百奥赛图-B股票所在的生物技术行业中,整体跌幅为2.37%。百奥赛图-B公司简介:北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240322144159791c31af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240322144159791c31af&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419694288","title":"百奥赛图-B(02315.HK)拟3月27日举行董事会会议考虑及批准全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2419694288","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2419694288?lang=zh_cn&edition=full","pubTime":"2024-03-15 16:46","pubTimestamp":1710492404,"startTime":"0","endTime":"0","summary":"格隆汇3月15日丨百奥赛图-B(02315.HK)公告,董事会会议将于2024年3月27日(星期三)举行,藉以(其中包括)(i)考虑及批准公司及其附属公司截至2023年12月31日止年度年度业绩及其发布,以及(ii)考虑派发末期股息(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151648128785e724&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151648128785e724&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419613635","title":"百奥赛图-B盘中异动 大幅拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2419613635","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419613635?lang=zh_cn&edition=full","pubTime":"2024-03-14 10:16","pubTimestamp":1710382593,"startTime":"0","endTime":"0","summary":"2024年03月14日早盘10时16分,百奥赛图-B股票出现波动,股价快速拉升5.10%。截至发稿,该股报10.700港元/股,成交量10000股,换手率0.01%,振幅5.11%。百奥赛图-B股票所在的生物技术行业中,整体涨幅为0.46%。百奥赛图-B公司简介:北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240314101633791a4a37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240314101633791a4a37&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419794865","title":"百奥赛图-B(02315)上涨5.4%,报10.54元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2419794865","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419794865?lang=zh_cn&edition=full","pubTime":"2024-03-13 15:59","pubTimestamp":1710316781,"startTime":"0","endTime":"0","summary":"3月13日,百奥赛图-B(02315)盘中上涨5.4%,截至15:59,报10.54元/股,成交130.64万元。百奥赛图(北京)医药科技股份有限公司是一家以创新技术驱动新药研发为主营业务的生物技术公司,拥有自主研发并拥有完全独立知识产权的全人抗体RenMiceTM平台,已建立起12项核心药物产品管线。公司正在对1000多个潜在可成药的靶点进行规模化药物开发,已签署了24项药物合作开发协议并与14家企业达成RenMice平台授权合作。截至2023年中报,百奥赛图-B营业总收入3.27亿元、净利润-1.9亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/13155939836189.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419905574","title":"百奥赛图-B盘中异动 股价大涨5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2419905574","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419905574?lang=zh_cn&edition=full","pubTime":"2024-03-13 15:59","pubTimestamp":1710316777,"startTime":"0","endTime":"0","summary":"2024年03月13日临近收盘15时59分,百奥赛图-B股票出现异动,股价大幅上涨5.39%。截至发稿,该股报10.540港元/股,成交量12.95万股,换手率0.12%,振幅7.40%。百奥赛图-B股票所在的生物技术行业中,整体涨幅为0.24%。百奥赛图-B公司简介:北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031315593787e78851&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031315593787e78851&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2418137958","title":"百奥赛图-B(02315)上涨7.18%,报10.0元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2418137958","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2418137958?lang=zh_cn&edition=full","pubTime":"2024-03-12 13:24","pubTimestamp":1710221099,"startTime":"0","endTime":"0","summary":"3月12日,百奥赛图-B(02315)盘中上涨7.18%,截至13:24,报10.0元/股,成交100.27万元。百奥赛图(北京)医药科技股份有限公司是一家以创新技术驱动新药研发为主营业务的生物技术公司,拥有自主研发并拥有完全独立知识产权的全人抗体RenMiceTM平台,已建立起12项核心药物产品管线。公司正在对1000多个潜在可成药的靶点进行规模化药物开发,已签署了24项药物合作开发协议并与14家企业达成RenMice平台授权合作。截至2023年中报,百奥赛图-B营业总收入3.27亿元、净利润-1.9亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/12132439815252.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2418776376","title":"百奥赛图-B盘中异动 下午盘大幅拉升5.04%报9.801港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2418776376","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2418776376?lang=zh_cn&edition=full","pubTime":"2024-03-12 13:21","pubTimestamp":1710220916,"startTime":"0","endTime":"0","summary":"2024年03月12日下午盘13时21分,百奥赛图-B股票出现波动,股价大幅拉升5.04%。截至发稿,该股报9.801港元/股,成交量9万股,换手率0.08%,振幅8.47%。百奥赛图-B股票所在的生物技术行业中,整体涨幅为1.73%。百奥赛图-B公司简介:北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403121321577919965a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403121321577919965a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2418876729","title":"百奥赛图-B盘中异动 大幅跳水6.02%报8.901港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2418876729","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2418876729?lang=zh_cn&edition=full","pubTime":"2024-03-11 09:37","pubTimestamp":1710121054,"startTime":"0","endTime":"0","summary":"2024年03月11日早盘09时37分,百奥赛图-B股票出现波动,股价急速下挫6.02%。截至发稿,该股报8.901港元/股,成交量2000股,换手率0.00%,振幅7.39%。百奥赛图-B股票所在的生物技术行业中,整体跌幅为0.12%。百奥赛图-B公司简介:北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031109373479192589&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031109373479192589&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417833085","title":"百奥赛图-B(02315)上涨6.43%,报9.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2417833085","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2417833085?lang=zh_cn&edition=full","pubTime":"2024-03-08 15:36","pubTimestamp":1709883379,"startTime":"0","endTime":"0","summary":"3月8日,百奥赛图-B(02315)盘中上涨6.43%,截至15:36,报9.1元/股,成交100.38万元。百奥赛图(北京)医药科技股份有限公司是一家以创新技术驱动新药研发为主营业务的生物技术公司,拥有自主研发并拥有完全独立知识产权的全人抗体RenMiceTM平台,已建立起12项核心药物产品管线。公司正在对1000多个潜在可成药的靶点进行规模化药物开发,已签署了24项药物合作开发协议并与14家企业达成RenMice平台授权合作。截至2023年中报,百奥赛图-B营业总收入3.27亿元、净利润-1.9亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/08153639782381.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2417707355","title":"百奥赛图-B盘中异动 股价大涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417707355","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417707355?lang=zh_cn&edition=full","pubTime":"2024-03-08 14:55","pubTimestamp":1709880938,"startTime":"0","endTime":"0","summary":"2024年03月08日下午盘14时55分,百奥赛图-B股票出现异动,股价急速拉升5.26%。截至发稿,该股报9.001港元/股,成交量9.8万股,换手率0.09%,振幅5.26%。资金方面,该股资金流入66.23万港元,流出13.6315万港元。百奥赛图-B股票所在的生物技术行业中,整体涨幅为1.22%。百奥赛图-B公司简介:北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030814553887e77469&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030814553887e77469&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417782694","title":"百奥赛图-B(02315)下跌5.0%,报8.55元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2417782694","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2417782694?lang=zh_cn&edition=full","pubTime":"2024-03-07 15:09","pubTimestamp":1709795364,"startTime":"0","endTime":"0","summary":"3月7日,百奥赛图-B(02315)盘中下跌5.0%,截至15:09,报8.55元/股,成交108.61万元。百奥赛图(北京)医药科技股份有限公司是一家以创新技术驱动新药研发为主营业务的生物技术公司,拥有自主研发并拥有完全独立知识产权的全人抗体RenMiceTM平台,已建立起12项核心药物产品管线。公司正在对1000多个潜在可成药的靶点进行规模化药物开发,已签署了24项药物合作开发协议并与14家企业达成RenMice平台授权合作。截至2023年中报,百奥赛图-B营业总收入3.27亿元、净利润-1.9亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/07150939765938.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2417978454","title":"百奥赛图-B盘中异动 下午盘股价大跌5.00%报8.551港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2417978454","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417978454?lang=zh_cn&edition=full","pubTime":"2024-03-07 15:03","pubTimestamp":1709795015,"startTime":"0","endTime":"0","summary":"2024年03月07日下午盘15时03分,百奥赛图-B股票出现波动,股价大幅下挫5.00%。截至发稿,该股报8.551港元/股,成交量10.35万股,换手率0.09%,振幅7.89%。资金方面,该股资金流入76.618万港元,流出7.75万港元。百奥赛图-B股票所在的生物技术行业中,整体跌幅为3.45%。百奥赛图-B公司简介:北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030715033587e76e7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030715033587e76e7a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417786401","title":"百奥赛图-B盘中异动 快速上涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417786401","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417786401?lang=zh_cn&edition=full","pubTime":"2024-03-06 09:49","pubTimestamp":1709689754,"startTime":"0","endTime":"0","summary":"2024年03月06日早盘09时49分,百奥赛图-B股票出现异动,股价急速拉升5.08%。截至发稿,该股报8.681港元/股,成交量63.008万股,换手率0.57%,振幅7.02%。机构评级方面,在所有1家参与评级的机构中,100%的券商给予卖出建议,无券商给予买入、持有建议。百奥赛图-B股票所在的生物技术行业中,整体涨幅为0.30%。百奥赛图-B公司简介:北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403060949147917b073&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403060949147917b073&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bbctg.com.cn","stockEarnings":[{"period":"1week","weight":-0.0389},{"period":"1month","weight":0.0347},{"period":"3month","weight":-0.278},{"period":"6month","weight":-0.4455},{"period":"1year","weight":-0.6505},{"period":"ytd","weight":-0.278}],"compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0149},{"period":"3month","weight":-0.0297},{"period":"6month","weight":-0.0712},{"period":"1year","weight":-0.1808},{"period":"ytd","weight":-0.0297}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。该公司运营两个业务部门。药物开发业务部门主要从事肿瘤学和自身免疫性疾病治疗的研发,及抗体开发业务。临床前研究服务部门主要从事基因编辑、临床前药理药效评估及模式动物销售。","exchange":"SEHK","name":"百奥赛图-B","nameEN":"BIOCYTOGEN-B"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥赛图-B(02315)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥赛图-B(02315)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥赛图-B,02315,百奥赛图-B股票,百奥赛图-B股票老虎,百奥赛图-B股票老虎国际,百奥赛图-B行情,百奥赛图-B股票行情,百奥赛图-B股价,百奥赛图-B股市,百奥赛图-B股票价格,百奥赛图-B股票交易,百奥赛图-B股票购买,百奥赛图-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥赛图-B(02315)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥赛图-B(02315)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}